Filing Details
- Accession Number:
- 0001127602-23-009755
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-10 16:27:29
- Reporting Period:
- 2023-03-09
- Accepted Time:
- 2023-03-10 16:27:29
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1145197 | Insulet Corp | PODD | Surgical & Medical Instruments & Apparatus (3841) | 043523891 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1665678 | Charles Alpuche | C/O Insulet Corporation 100 Nagog Park Acton MA 01720 | Advisor | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-03-09 | 4,000 | $31.21 | 49,584 | No | 4 | M | Direct | |
Common Stock | Disposition | 2023-03-09 | 4,000 | $290.90 | 45,584 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2023-03-09 | 4,000 | $0.00 | 4,000 | $31.21 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
35,748 | 2026-02-03 | No | 4 | M | Direct |
Footnotes
- The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $290.89 to $291.18. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.